Lumbrokinase References

Boluoke® (Lumbrokinase)

Corio PSP™ (Coriolus Versicolor)

CordImmune™ (Cordyceps Sinensis)

Fan Q, Wu C, et al. Some features of intestinal absorption of intact fibrinolytic enzyme III-1 from Lumbricus rubellus. Biochem Biophys Acta, 2001; 1526(3): 286-92

Gao Y, Qin MZ. Lumbrokinase in treatment of patients with hyperfibrinogenemia of coronary atherogenesis disease. Journal of Capital University of Medical Sciences, 1999; 4(20)

Gong B, Wu XY. Observation of using Baiao lumbrokinase capsules to treat ischemic cerebrovascular accident with hyperlipidemia. Capital Medicine, 2000; 7(12): 39

Guo ZF, Liu XX. Observation of treating ischemic cerebrovascular accident with Baiao lumbrokinase capsules. Capital Medicine, 2000; 7(11): 45

Huang ZD, Li ZW, Zhang WX. Lumbrokinase in treating cerebral infarction. Chinese Journal of New Drugs and Clinical Remedies, 2000; 6(19): 453-455

Jie WH. Clinical observation of treating unstable angina in seniors with lumbrokinase. Capital Medicine, 2000; 7(10): 37

Jin L, Jin H, Zhang G, Xu G. Changes in coagulation and tissue plasminogen activator after the treatment of cerebral infarction with lumbrokinase. Chinese Journal of Microcirculation, 2000; 23: 213-218.

Jing LR, Xu GZ. Dynamics of fibrinolysis and hemostasis in ischemic stroke patients, and the effects of lumbrokinase on those dynamics. Chinses Journal of New Drugs and Clinical Remedies, 1999; 18(1): 48-49

Liao RH. Analytical report of treating 30 patients of ischemic cerebrovascular disease with Panford lumbrokinase and nimodipine. Strait Pharmaceutical Journal, 1997; 9(3): 25-26

Liu J, Zhou LM, Ren Y. Lumbrokinase capsule vs Salvia miltiorrhiza tablet in treating coronary disease with angina pectoris. Chinese Journal of New Drugs and Clinical Remedies, 1999; 1(18): 17-19

Mihara H, Sumi H, Mizumotoh, et el. Oral administration of earthworm powder as a possible thrombolytic therapy ed In: Tamkak, Recent advance in thrombosis and fibrinolysis. Hapan Academic Press, 1996, 287.

Mihara H, Sumi H, Yoneta T, Mizumoto H, et al. A novel fibrinolytic enzyme extracted from the earthworm, Lumbricus rubellus. Jpn J Physiol, 1991; 41: 461-72.

Mihara H. A possibility of Earthworm powder as therapeutic agent for thrombosis. Thromb Haemost, 1988; 50: 258.

Pan SY. Treating Blood-Stagnation type angina with Baiao lumbrokinase. Capital Medicine, 1998; 9(5):40-41

Pang SQ, Ding MC, Xie SP, et al. A clinical study of therapeutic effectiveness in treating ischemic cerebrovascular disease with Lumbrokinase (Boluoke). Chinese Journal of Neurology and Psychiatry, 1993; 26(4): 229.OOOOOPark S, Kye KC, Sumi H, et al. Fibrinolytic activity of the earthworm extract. Thromb Haemost, 1989; 62: 545.

Park Y, Ryu E, Kim H, Jeong J, et al. Characterization of antithrombotic activity of lumbrokinase-immobilized polyurethane valves in the total artificial heart. Artif Organs,1999; 23: 210-4.

Qi W, Yu XB, et al. Effects of lumbrokinase on blood rheology of seniors with coronary arterial diseases. Chinese Journal of Microcirculation, 2000; 1(10): 55

Ryu GH, Park S, Kim M, et al. Antighrombogenicity of lumbrokinase-immobilized polyurethane. J Biomed Mater Res, 1994; 28: 1069-77.

Tang Y, Liang D, et al. Crystal structure of earthworm fibrinolytic enzyme component a: revealing the structural determinants of its dual fibrinolytic activity. J Mol Biol, 2002; 32(1): 57-68

Wang LH, Yao W. Vermis kinase (Boluoke) therapeutic evaluation to cerebral infarction and influence to blood rheology. Journal of Practical Medical Technology, 1998; 5(2).

Wang R, Chen Q, Fang XQ, et al. Effects of Fleroxacin combined with urokinase or earthworm kinase on bacterial biofilm. Acta Pharmaceutica Sinica, 1999; 9(34):662-665

Wang XL, Yan DC. Clinical observation of using Baiao lumbrokinase capsules to treat patients with coronary artery disease secondary to diabetes mellitus. Capital Medicine, 2000; 7(8): 38

Wu XQ, Wu C, et al. Immobilized earthworm fibrinolytic enzyme III-1 with carbonyldiimidazole activated agarose. Protein and Peptide Letters, 2002: 9(1): 75-80

Yang GR. Treating unstable angina with Baiao lumbrokinase capsules. Capital Medicine. 1999; 3(6): 30

Zhang GP, Jin HM, Zhang M, et al. Anticoagulative and fibrinolytic effects of lumbrokinase and their relation to tissue plasminogen activator. Chinese Journal of Geriatrics, 1998; 6(17): 366-368

Zhang GP, Qian RZ, et al. Experimental observation of the inhibitory effects of lumbrokinase on platelets. National Medical Journal of China, 1998; 5(78): 394-95

Zhang HY. Clinical evaluation of treating acute ischemic cerebrovascular disease with lumbrokinase. Capital Medicine, 2000; 7(3): 45-46

Zhang JQ, Jing CH. Clinical evaluation of using Baiao lumbrokinase in the treatment of central retinal vein occlusion. Capital Medicine, 1999; 6(2): 51

Zhang LP, et al. Preventative effects of lumbrokinase on experimentally induced emboli. Chinese Journal of Hemorheology, 1995, 11(10): 679-680

Zhang NH. Blood rheological changes of coronary artery disease patients prior and after lumbrokinase treatment. Chinese Journal of Hemorheology, 1999; 1(9): 63

Zheng HJ, Xu JM, Huang ZH. Lumbrkinase capsule vs ticlopidine in treating coronary artery disease with angina pectoris. Chinses Journal of New Drugs and Clinical Remedies, 2000; 5(19): 406-408

Zheng Z, Lin JN, et al. Observation of 20 unstable angina patients treated with Baiao lumbrokinase capsules. Capital Medicine, 2000; 7(6): 38

Zhao J, Fan R, et al. Assay of lumbrokinase with a chromophoric substrate. Protein and Peptide Letters, 1997; 4(6): 409-14

Zhou M, Wang FQ. The effects of lumbrokinase on blood rheology in patients with sudden hearing loss. Journal of Chinese Microcirculation, 2000; 3(4): 177-178

Zhou XD, Zhao RX, Zheng XR, Zhang H. Observation of Boluoke (lumbrokinase) treatment in the recovery of motor function after cerebral infarction. Chinese Journal of Western and Chinese Medicine Cooperation, 1997; 12 (17).

* The statements above have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.